ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO134

Role of Etelcalcetide in the Management of Secondary Hyperparathyroidism: Clinical Experience

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical

Authors

  • Moliz, Candela, Hospital Universitario 12 de Octubre, Madrid, Spain
  • Canllavi fiel, Elizabeth, Hospital Universitario 12 de Octubre, Madrid, Spain
  • Redondo navarro, Beatriz, Hospital Universitario 12 de Octubre, Madrid, Spain
  • Fernández vidal, María, Hospital Universitario 12 de Octubre, Madrid, Spain
  • Bada Bosch, Teresa, Hospital Universitario 12 de Octubre, Madrid, Spain
  • Trujillo Cuellar, Hernando, Hospital Universitario 12 de Octubre, Madrid, Spain
  • Aubert, Lucia, Hospital Universitario 12 de Octubre, Madrid, Spain
  • Sandino Perez, Justo, Hospital Universitario 12 de Octubre, Madrid, Spain
  • Gutierrez-solis, Elena, Hospital Universitario 12 de Octubre, Madrid, Spain
  • Merida, Evangelina, Hospital Universitario 12 de Octubre, Madrid, Spain
Background

Etelcalcetide is the first intravenous calcimimetic authorized for the treatment of SHPT in haemodialysis (HD). It has proven to be effective in lowering parathyroid hormone (PTH), with an acceptable and comparable safety profile. There have only been a few reports regarding treatment of SHPT using etelcalcetide in clinical practice.

Methods

The aim of this deriptive study was to evaluate the results of using etelcalcetide in patients on HD with SHPT.

Results

Thirty patients on HD received etelcalcetide were enrolled (figure 1). The minimum observation period was 6 months. Fifteen (50%) were previously with cinacalcet (group 1) and 15 (50%) received etelcalcetide at onset (group 2). In global, serum PTH levels were significantly decreased at the end of follow up compared to baseline levels ( PTH pretreatment 784 +/- 707 (p 0.0077) vs PTH end of follow- up
671 +/- 680 (p 0.0077) ). When comparing both groups, we found a significant decrease of Ca, P and PTH in group 2. However, we only found significant decrease of Ca in group 1 (figure 2). The dosage of calcium binders (33.3% pretreatment vs 56.7% at the end of follow-up, p 0.054), non-calcium binders (40% pretreatment vs 63.3% at the end of follow-up, p 0.02) and vitamin D analogues (56,7% pretreatment vs 66,7% at the end of follow-up, p 0,3) were increased when etelcalcetide treatment was started. No changes were made in dialysate calcium concentration. Six patients, presented hypocalcemia (Ca < 7.5 mEq/l)

Conclusion

In our cohort, etelcalcetide has shown to be effective in reducing serum PTH. An increase in the use of vitamin D analogues, calcium binders and non-calcium binders has been observed, probably due to the hypocalcemia.

Funding

  • Government Support - Non-U.S.